Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (FREESIA-1)

Last Updated   May 14, 2025

Want to learn how to participate in this trial?

80202135FNAIT3001

OVERVIEW

  • Sexes Eligible for Study
    female
  • Age
    18+ years
  • Phase
    phase 3
  • Sites
    20 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

CONDITIONS

  • Thrombocytopenia, Neonatal Alloimmune

ELIGIBILITY


Inclusion Criteria:

* Has a history of greater than or equal to (>=) 1 prior pregnancy with fetal and neonatal alloimmune thrombocytopenia (FNAIT) (including neonatal platelet count less than (<) 150×10^9/Liter) with none of them affected by fetal/neonatal intracranial hemorrhage (ICH) or severe hemorrhage based on medical records
* Current pregnancy with presence of maternal anti- human platelet antigen (HPA)-1a alloantibody and positive fetal HPA-1a genotype as confirmed by cell-free fetal deoxyribonucleic acid (DNA) in maternal blood
* Health status considered stable by the investigator based on physical examination, medical history, vital signs, 12-lead Electrocardiogram (ECG), and clinical laboratory tests performed at screening
* For maternal participant and neonate/infant, willing to forego participation in another clinical study of an investigational therapy until the last follow-up visit


Exclusion Criteria:

* Currently pregnant with multiple gestations (twins or more)
* History of severe preeclampsia in a previous pregnancy
* History of myocardial infarction, unstable ischemic heart disease, or stroke
* Known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients (refer to the Investigator Brochure (IB))
* Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant


Inclusion Criteria:

* Has a history of greater than or equal to (>=) 1 prior pregnancy with fetal and neonatal alloimmune thrombocytopenia (FNAIT) (including neonatal platelet count less than (<) 150×10^9/Liter) with none of them affected by fetal/neonatal intracranial hemorrhage (I

More...

DETAILS

LOCATIONS

Locations in:
Belgium, Italy, Norway, Slovakia, Spain, Sweden, Brazil, France, Hungary, Slovenia, Switzerland, Israel
Country (12) City or Province (20) Status
Belgium Leuven Universitair Ziekenhuis Leuven
RECRUITING
Italy Rome Fondazione Policlinico Universitario A Gemelli IRCCS
RECRUITING
Norway Bergen Haukeland University Hospital
RECRUITING
Norway Oslo Oslo University Hospital HF Ulleval sykehus
RECRUITING
Slovakia Kosice Univerzitna nemocnica L. Pasteura Kosice
RECRUITING
Slovakia Martin Univerzitná nemocnica Martin
RECRUITING
Spain Sevilla Hosp. Virgen Del Rocio
RECRUITING
Sweden Stockholm Karolinska Universitetssjukhuset Huddinge
RECRUITING
Brazil Recife Instituto de Medicina Integral Professor Fernando Figueira
RECRUITING
Brazil Rio de Janeiro Instituto D Or de Pesquisa e Ensino IDOR
RECRUITING
Brazil Sao Paulo Hospital Das Clinicas Da Faculdade De Medicina Da USP
RECRUITING
France Lille CHRU Lille
RECRUITING
France Paris Hopital trousseau- APHP
RECRUITING
Hungary Budapest Semmelweis Egyetem
RECRUITING
Norway Tromso Universitetssykehuset Nord-Norge HF
RECRUITING
Norway Trondheim St. Olavs Hospital
RECRUITING
Slovenia Ljubljana Univerzitetni klinicni center Ljubljana
RECRUITING
Switzerland Lausanne Centre Hospitalier Universitaire Vaudois CHUV
RECRUITING
Israel Ramat Gan Sheba Medical Center
RECRUITING
Slovakia Nove Zamky Fakultna nemocnica s poliklinikou Nove Zamky
RECRUITING
Show More
Geo Locations

50.87959, 4.70093

41.89193, 12.51133

60.39299, 5.32415

59.91273, 10.74609

48.71395, 21.25808

49.06651, 18.92399

37.38283, -5.97317

59.33258, 18.0649

-8.05389, -34.88111

-22.90278, -43.2075

-23.5475, -46.63611

50.63297, 3.05858

48.85341, 2.3488

47.49801, 19.03991

69.6489, 18.95508

63.43049, 10.39506

46.05108, 14.50513

46.516, 6.63282

32.08227, 34.81065

47.98544, 18.16195

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.